R Squared’s Mirum Pharmaceuticals MIRM Stock Holding History

R Squared’s Portfolio MIRM Stock Details MIRM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-1,680	Closed	-$69.5K	–	1002
2024 Q4	$69.5K	Buy	+1,680	New	+$70K	0.07%	373

Other funds holding MIRM

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

NHAS

Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

R Squared's MIRM Position: Q1 2025 in Review

R Squared sold out of Mirum Pharmaceuticals (MIRM) in Q1 2025, closing a stake of 1,680 shares — an estimated $69.5K sold.

R Squared first reported a position in MIRM in Q4 2024 and held it in 1 quarter. The position peaked at $69.5K in Q4 2024. 214 funds tracked by Wall St. Rank hold MIRM as of Q1 2025.

R Squared reported no remaining Mirum Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
R Squared sold 1,680 Mirum Pharmaceuticals shares in Q1 2025, an estimated $69.5K.
R Squared first reported a position in Mirum Pharmaceuticals in Q4 2024 and held it in 1 quarter.
R Squared's Mirum Pharmaceuticals position peaked at $69.5K in Q4 2024.
214 funds tracked by Wall St. Rank held Mirum Pharmaceuticals as of Q1 2025.

Based on R Squared's 13F filing for Q1 2025, filed 9 May 2025.